Nat. Rev. Cardiol. doi: /nrcardio

Slides:

Advertisements

Similar presentations

Ghanem et al., J Am Coll Cardiol 2010;55:1427–32..

Advertisements

ACC 2015 Michael J Reardon, MD, FACC On Behalf of the CoreValve US Investigators A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic.

Impact of Concomitant Tricuspid Annuloplasty on Tricuspid Regurgitation Right Ventricular Function and Pulmonary Artery Hypertension After Degenerative.

© 2012 EuroIntervention. All rights reserved. EuroIntervention 2009;5: A comparison of patient characteristics and 30-day mortality outcomes after.

From: Incidence, Predictive Factors, and Prognostic Value of New-Onset Atrial Fibrillation Following Transcatheter Aortic Valve Implantation J Am Coll.

Management of mitral regurgitation. See legend for Fig

Figure 1 Initial management of a patient with acute heart failure

Mitral Regurgitation: Epidemiology, Pathophysiology and When to Repair

From: Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve ReplacementA Systematic Review and Meta-analysis Ann Intern Med. 2016;165(5):

Valvular Heart Disease: Classic Teaching and Emerging Paradigms

Nat. Rev. Cardiol. doi: /nrcardio

Figure 10 Assessment of myocardial fibrosis

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Reproduced with permission from Yancy, C. W. et al. 2017

Figure 4 BMI and mortality in patients with heart failure

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Pathological specimens showing the most common reasons for bioprosthetic valve failure Figure 2 | Pathological specimens showing the most common.

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Imaging characteristics of cardiac myxoma

Update in Cardiac and Thoracic Surgery

Figure 2 Three-year survival rates on the basis of body composition

Figure 3 3D printing of aortic and mitral valves

Figure 8 4D magnetic resonance imaging patterns

Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications.

Figure 4 Valve-in-valve implantations in degenerated surgical valves

Figure 2 Results of diastolic stress testing

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Management of Patients With Aortic Valve Stenosis

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Cardiovascular risk and disease across the life-course

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 A patient with aortic and mitral stenosis

Aspects to be considered by the Heart Team for the decision between TAVR and SAVR in patients at increased surgical risk. Aspects to be considered by the.

Figure 4 TAVI for bicuspid aortic valve disease

Figure 1 Types of surgical and transcatheter aortic valves

Figure 2 Global cost of HF per capita in 2012

Figure 2 A patient with aortic stenosis and mitral regurgitation

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Challenges for big data applications in cardiovascular care

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Effects of cardiovascular medication on the fetus

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 U‑shape relationship between exercise dose and risk of atrial fibrillation (AF) Figure 3 | U-shape relationship between exercise dose and risk.

Nat. Rev. Cardiol. doi: /nrcardio

Suggested pathway for assessment of aortic valve replacement dysfunction. Suggested pathway for assessment of aortic valve replacement dysfunction. Transthoracic.

Cost-effectiveness of the Edwards SAPIEN transcatheter heart valve compared with standard management and surgical aortic valve replacement in patients.

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Baseline Clinical Characteristics

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Thomas A. Treibel et al. JACC 2018;71:

N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels for patients undergoing surgical aortic valve replacement (SAVR) (A), patients undergoing.

Rick A. Nishimura et al. JACC 2014;63:e57-e185

Nat. Rev. Cardiol. doi: /nrcardio

Rick A. Nishimura et al. JACC 2017;70:

Nat. Rev. Cardiol. doi: /nrcardio

Presentation transcript:

Nat. Rev. Cardiol. doi:10.1038/nrcardio.2016.57 Figure 5 Management of severe aortic stenosis requiring surgery, with concomitant mitral regurgitation Figure 5 | Management of severe aortic stenosis requiring surgery, with concomitant mitral regurgitation. Mitral regurgitation is highly likely to improve with aortic valve replacement in the absence of atrial fibrillation, left atrial dilatation, or pulmonary hypertension. This algorithm requires validation by further studies. *A staged approach is possible, consisting of TAVI followed by implantation of a MitraClip® (Evalve, Inc., USA) if symptomatic mitral regurgitation persists. SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation. Modified from Nombela-Franco, L. et al. Significant mitral regurgitation left untreated at the time of aortic valve replacement: a comprehensive review of a frequent entity in the transcatheter aortic valve replacement era. J. Am. Coll. Cardiol. 63 (24), 2643–2658 © (2014), with permission from Elsevier. Modified from Nombela-Franco, L. et al. Significant mitral regurgitation left untreated at the time of aortic valve replacement: a comprehensive review of a frequent entity in the transcatheter aortic valve replacement era. J. Am. Coll. Cardiol. 63 (24), 2643–2658 © (2014), with permission from Elsevier Unger, P. et al. (2016) Pathophysiology and management of multivalvular disease Nat. Rev. Cardiol. doi:10.1038/nrcardio.2016.57